Trials / Unknown
UnknownNCT03801577
Hepaxa Management of Non-alcoholic Fatty Liver Disease
Hepaxa Management of Non-Alcoholic Fatty Liver Disease (NAFLD): A Real-world Pilot Study Observing Effects of Nutritional Management With Hepaxa in Subjects With Liver Steatosis
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- BASF AS · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study measures the steatosis in patients With fatty livers as determined by CAP score from a fibroscan assessment. The study attempts to determine the effect of using the Medical Food Hepaxa in a Clinical setting Close to real-world use.
Detailed description
Subjects With fatty liver are given Hepaxa for 6 months. Fibroscan CAP measurements are taken at 3 monthly intervals. Subjects consent to Collection of data from approximately 6 months prior to use of Hepaxa. Patients unresponsive to life style recommendations given as standard practice will be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Hepaxa | High concentrate EPA and DHA |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2019-10-01
- Completion
- 2019-12-01
- First posted
- 2019-01-11
- Last updated
- 2019-01-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03801577. Inclusion in this directory is not an endorsement.